Improvement of the synthesis and pharmacokinetic properties of chromenotriazolopyrimidine MDM2-p53 protein-protein inhibitors

被引：35

作者：

Beck, Hilary P. ^{[1
]}

DeGraffenreid, Michael ^{[1
]}

Fox, Brian ^{[1
]}

Allen, John G. ^{[2
]}

Rew, Yosup ^{[1
]}

Schneider, Stephen ^{[3
]}

Saiki, Anne Y. ^{[4
]}

Yu, Dongyin ^{[4
]}

Oliner, Jonathan D. ^{[4
]}

Salyers, Kevin ^{[5
]}

Ye, Qiuping ^{[6
]}

Olson, Steven ^{[1
]}

机构：

[1] Amgen Inc, Chem Res & Discovery, San Francisco, CA 94080 USA

[2] Amgen Inc, Chem Res & Discovery, Thousand Oaks, CA 91320 USA

[3] Amgen Inc, Chem Res & Discovery, Cambridge, MA 02142 USA

[4] Amgen Inc, Oncol Res, Thousand Oaks, CA 91320 USA

[5] Amgen Inc, PKDM, Thousand Oaks, CA 91320 USA

[6] Amgen Inc, PKDM, San Francisco, CA 94080 USA

来源：

BIOORGANIC & MEDICINAL CHEMISTRY LETTERS | 2011年 / 21卷 / 09期

关键词：

Oncology; Protein-protein interaction; Pharmacokinetics; SMALL-MOLECULE INHIBITORS; CANCER-THERAPY; P53; AMPLIFICATION; APOPTOSIS; STABILITY; BINDING;

D O I：

10.1016/j.bmcl.2010.11.027

中图分类号：

R914 [药物化学];

学科分类号：

100701 ;

摘要：

Human murine double minute 2 (MDM2) is a negative regulator of p53, which plays an important role in cell cycle and apoptosis. We report several optimizations to the synthesis of the chromenotriazolopyrimidine series of MDM2-p53 protein-protein interaction inhibitors. Additionally, the in vitro and in vivo stability, pharmacokinetic properties and solubility were improved through N-substitution. (C) 2010 Elsevier Ltd. All rights reserved.

引用

页码：2752 / 2755

页数：4

共 16 条

[1] Discovery and Optimization of Chromenotriazolopyrimidines as Potent Inhibitors of the Mouse Double Minute 2-Tumor Protein 53 Protein-Protein Interaction [J].

Allen, John G. ;

Bourbeau, Matthew P. ;

Wohlhieter, G. Erich ;

Bartberger, Michael D. ;

Michelsen, Klaus ;

Hungate, Randall ;

Gadwood, Robert C. ;

Gaston, Rick D. ;

Evans, Bruce ;

Mann, Larry W. ;

Matison, Michael E. ;

Schneider, Stephen ;

Huang, Xin ;

Yu, Dongyin ;

Andrews, Paul S. ;

Reichelt, Andreas ;

Long, Alexander M. ;

Yakowec, Peter ;

Yang, Evelyn Y. ;

Lee, Tani Ann ;

Oliner, Jonathan D. .

JOURNAL OF MEDICINAL CHEMISTRY, 2009, 52 (22) :7044-7053

[2] Control of apoptosis by p53 [J].

Fridman, JS ;

Lowe, SW .

ONCOGENE, 2003, 22 (56) :9030-9040

[3] Mdm2 promotes the rapid degradation of p53 [J].

Haupt, Y ;

Maya, R ;

Kazaz, A ;

Oren, M .

NATURE, 1997, 387 (6630) :296-299

[4] Small molecule inhibitors of the p53-MDM2 [J].

Hu, Chun-Qi ;

Hu, Yong-Zhou .

CURRENT MEDICINAL CHEMISTRY, 2008, 15 (17) :1720-1730

[5] Development of a binding assay for p53/HDM2 by using homogeneous time-resolved fluorescence [J].

Kane, SA ;

Fleener, CA ;

Zhang, YS ;

Davis, LJ ;

Musselman, AL ;

Huang, PS .

ANALYTICAL BIOCHEMISTRY, 2000, 278 (01) :29-38

[6] Regulation of p53 stability by Mdm2 [J].

Kubbutat, MHG ;

Jones, SN ;

Vousden, KH .

NATURE, 1997, 387 (6630) :299-303

[7] Novel 1,4-benzodiazepine-2,5-diones as Hdm2 antagonists with improved cellular activity [J].

Leonard, Kristi ;

Marugan, Juan Jose ;

Raboisson, Pierre ;

Calvo, Raul ;

Gushue, Joan M. ;

Koblish, Holly K. ;

Lattanze, Jennifer ;

Zhao, Shuyuan ;

Cummings, Maxwell D. ;

Player, Mark R. ;

Maroney, Anna C. ;

Lu, Tianbao .

BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2006, 16 (13) :3463-3468

[8] p53 protein stability in tumour cells is not determined by mutation but is dependent on Mdm2 binding [J].

Midgley, CA ;

Lane, DP .

ONCOGENE, 1997, 15 (10) :1179-1189

[9] ONCOPROTEIN MDM2 CONCEALS THE ACTIVATION DOMAIN OF TUMOR SUPPRESSOR-P53 [J].

OLINER, JD ;

PIETENPOL, JA ;

THIAGALINGAM, S ;

GVURIS, J ;

KINZLER, KW ;

VOGELSTEIN, B .

NATURE, 1993, 362 (6423) :857-860

[10] AMPLIFICATION OF A GENE ENCODING A P53-ASSOCIATED PROTEIN IN HUMAN SARCOMAS [J].

OLINER, JD ;

KINZLER, KW ;

MELTZER, PS ;

GEORGE, DL ;

VOGELSTEIN, B .

NATURE, 1992, 358 (6381) :80-83

← 1 2 →